Avalo Therapeutics, Inc.
AVTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AVTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVTX
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based therapies, with its lead candidate abdakibart (AVTX-009) in Phase 2 for hidradenitis suppurativa and a topline readout expected by year-end 2026.
Key risk: Clinical trial failure
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.05B
Cash Runway
58.1 moLead Asset
abdakibart (Phase 2)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial · 1 catalyst for Avalo Therapeutics, Inc..
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based therapies, with its lead candidate abdakibart (AVTX-009) in Phase 2 for hidradenitis suppurativa and a topline readout expected by year-end 2026.
- Avalo is a clinical-stage biotechnology company dedicated to developing IL-1β-based therapeutics [sec_mda · as of 2026-05-13].
- Lead candidate abdakibart (AVTX-009) is in a Phase 2 LOTUS trial for hidradenitis suppurativa (HS) [sec_mda · as of 2026-03-23].
- As of June 30, 2026, the company reported cash & equivalents of $85.6M and shareholders' equity of $104.6M [sec].
- Net income for the six months ended June 30, 2026 was -$36.4M [sec].
- A Phase 2 topline data readout for avtx-009 is anticipated by December 31, 2026 [upcoming catalysts].
What works
- Avalo's lead candidate abdakibart has shown statistically significant benefit in key secondary endpoints in a Phase 2 trial for hidradenitis suppurativa, including HiSCR50, change in IHS4, and change in draining tunnel count [sec_mda · as of 2026-08-06].
- The company completed an equity offering in Q2 2026 for net proceeds of $405.0 million, providing substantial capital to fund operations and development [sec_mda · as of 2026-08-06].
- Avalo has a clear near-term catalyst with the anticipated Phase 2 topline readout for avtx-009 by year-end 2026 [upcoming catalysts].
What to weigh
- Avalo has incurred significant operating losses since inception, with a net loss of $36.4M in the first half of 2026 alone [sec].
- The company is dependent on the success of its lead candidate abdakibart, and any negative trial results could materially impact its prospects [sec_mda · as of 2026-08-06].
- Avalo may need to raise additional capital through equity offerings, collaborations, or licensing, which could dilute existing stockholders or require relinquishing valuable rights [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Avalo is a clinical-stage biotechnology company focused on IL-1β-based therapies.
“We are a clinical stage biotechnology company fully dedicated to developing IL-1β-bas”
SEC MD&A · May 13, 2026
Abdakibart demonstrated statistically significant benefit on key secondary endpoints in HS.
“Abdakibart also demonstrated statistically significant benefit across the key secondary endpoints, including HiSCR50, change in IHS4, and change in draining tunnel count.”
SEC MD&A · August 6, 2026
Avalo completed an equity offering for net proceeds of $405.0 million in Q2 2026.
“in the second quarter of 2026, we completed an equity offering for net proceeds of $405.0 million.”
SEC MD&A · August 6, 2026
The Phase 2 LOTUS trial topline data readout is anticipated in Q2 2026.
“preparing for the anticipated topline data readout in the second quarter of 2026”
SEC MD&A · March 23, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · avtx-009 — Phase 2 Readout: avtx-009 — Topline data from the Phase 2 LOTUS trial for abdakibart in hidradenitis suppurativa is expected, which will inform the program's advancement to Phase 3.
Risks & what to watch (3)›
Key risks
- Clinical trial failure — Negative Phase 2 results for abdakibart could severely impact the company's pipeline and stock value [sec_mda · as of 2026-08-06].
- Capital needs and dilution — Ongoing losses may require additional financing, potentially diluting existing shareholders [sec_mda · as of 2026-08-06].
- Single-product dependency — Avalo's near-term value is heavily tied to the success of its lead candidate abdakibart [sec_mda · as of 2026-08-06].
What to watch
- Phase 2 topline data readout for avtx-009 expected by December 31, 2026 [upcoming catalysts].
- Cash burn rate and any additional financing activities following the $405M equity raise [sec_mda · as of 2026-08-06].
- Progress in planning for Phase 3 trials for abdakibart [sec_mda · as of 2026-03-23].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Avalo Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Avalo Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
58.1 months
D/E 0.09 · 0% dilution
Lead: Phase 2
2 candidates
1 upcoming, next in ~123d
0 buys · 38 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
96
Total value held
$423.3M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 2,879,481 | $43.0M |
| caligan partners lp | 1,635,023 | $24.4M |
| bvf inc/il | 1,632,845 | $24.4M |
| vanguard capital management llc | 1,439,388 | $21.5M |
| affinity asset advisors, llc | 1,340,840 | $20.0M |
| logos global management lp | 1,300,000 | $19.4M |
| caption management, llc | 1,086,700 | $16.2M |
| farallon capital management llc | 916,000 | $13.7M |
| rtw investments, lp | 856,962 | $12.8M |
| adage capital partners gp, l.l.c. | 854,000 | $12.8M |
Showing top 10 of 96 institutional holders of Avalo Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 21.5%
- Days to cover
- 7.3
- Shares short
- 5,733,586
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AVTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Avalo Therapeutics, Inc.?
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based therapies, with its lead candidate abdakibart (AVTX-009) in Phase 2 for hidradenitis suppurativa and a topline readout expected by year-end 2026.
What is Avalo Therapeutics, Inc.'s lead drug candidate?
Avalo Therapeutics, Inc.'s most advanced tracked candidate is abdakibart (Phase 2) for hidradenitis suppurativa.
What is Avalo Therapeutics, Inc.'s next catalyst?
Avalo Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: avtx-009" — expected December 31, 2026.
Who is the CEO of Avalo Therapeutics, Inc.?
Dr. Garry A. Neil M.D. is the chief executive officer of Avalo Therapeutics, Inc. (AVTX).
Where is Avalo Therapeutics, Inc. headquartered?
Avalo Therapeutics, Inc. (AVTX) is headquartered in Wayne, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.